Search research articles
Contact Us
Filters
Showing results (101-110 of 142) with videos related to
Page
of 15
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 9, 2026
Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis
Pauline Corbaux, Benoit You, Iain McNeish, et al.
Gynecologic Oncology
|
April 27, 2023
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients
Thibault Gauduchon, Maria Kfoury, Domenica Lorusso, et al.
JAMA Oncology
|
May 13, 2022
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial
Pierre Heudel, Jean-Sébastien Frenel, Cécile Dalban, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 19, 2025
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis
Pauline Corbaux, Benoit You, Tatsuo Kagimura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2020
Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial
Benoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, et al.
Gynecologic Oncology
|
March 6, 2025
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery
Claudia Marchetti, Raffaella Ergasti, Filippo Maria Capomacchia, et al.
Cancer Discovery
|
October 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2023
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis
Pauline Corbaux, Benoit You, Rosalind M Glasspool, et al.
Frontiers in Oncology
|
August 5, 2022
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T<sub>H</sub>1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study
Magali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, et al.
Gynecologic Oncology
|
July 27, 2020
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)
Patrick Robelin, Michel Tod, Olivier Colomban, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 142) with videos related to
Sort By:
Page
of 15
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 9, 2026
Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis
Pauline Corbaux, Benoit You, Iain McNeish, et al.
Gynecologic Oncology
|
April 27, 2023
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients
Thibault Gauduchon, Maria Kfoury, Domenica Lorusso, et al.
JAMA Oncology
|
May 13, 2022
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial
Pierre Heudel, Jean-Sébastien Frenel, Cécile Dalban, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 19, 2025
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis
Pauline Corbaux, Benoit You, Tatsuo Kagimura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2020
Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial
Benoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, et al.
Gynecologic Oncology
|
March 6, 2025
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery
Claudia Marchetti, Raffaella Ergasti, Filippo Maria Capomacchia, et al.
Cancer Discovery
|
October 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2023
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis
Pauline Corbaux, Benoit You, Rosalind M Glasspool, et al.
Frontiers in Oncology
|
August 5, 2022
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T<sub>H</sub>1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study
Magali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, et al.
Gynecologic Oncology
|
July 27, 2020
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)
Patrick Robelin, Michel Tod, Olivier Colomban, et al.
Page
of 15